The Business Review
Date: Friday, September 16, 2011, 7:12am EDT

GE Healthcare    announced that it plans to dedicate $1 billion of its total research and development budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities.

Part of those funds will also be dedicated toward advancing its technologies for the production of biopharmaceuticals and for cancer research.

The investment crosses all lines of GE Healthcare’s global business and will enable the company to bring ideas to market designed to improve accuracy of diagnosis to enable more effective treatment decisions and empower doctors and patients with better information, according to company management.

“We are committed to tackling cancer. However, with a disease as complex and multifaceted as cancer, solutions need to be equally multifaceted and even more integrated, combining imaging, molecular diagnostics and health care information technology,” said John Dineen, president and CEO of GE Healthcare. “As one of the most relevant global cancer diagnostic companies, we are devoting an even greater share of our R&D budget to continue developing new oncology solutions.”

United Kingdom-based GE Healthcare has operations North Greenbush in Rensselaer County and conducts research at GE's Global Research Center in Niskayuna in Schenectady County.

(The Business Review)
http://www.bizjournals.com/alb.....amp;s=article_search

Quoted from Box A Rox

The Business Review
Date: Friday, September 16, 2011, 7:12am EDT

GE Healthcare    announced that it plans to dedicate $1 billion of its total research and development budget over the next five years to expand its advanced cancer diagnostic and molecular imaging capabilities.

Part of those funds will also be dedicated toward advancing its technologies for the production of biopharmaceuticals and for cancer research.

The investment crosses all lines of GE Healthcare’s global business and will enable the company to bring ideas to market designed to improve accuracy of diagnosis to enable more effective treatment decisions and empower doctors and patients with better information, according to company management.

“We are committed to tackling cancer. However, with a disease as complex and multifaceted as cancer, solutions need to be equally multifaceted and even more integrated, combining imaging, molecular diagnostics and health care information technology,” said John Dineen, president and CEO of GE Healthcare. “As one of the most relevant global cancer diagnostic companies, we are devoting an even greater share of our R&D budget to continue developing new oncology solutions.”

United Kingdom-based GE Healthcare has operations North Greenbush in Rensselaer County and conducts research at GE's Global Research Center in Niskayuna in Schenectady County.

(The Business Review)
http://www.bizjournals.com/alb.....amp;s=article_search

Now, if can just get the jobs czar Imelt to have his corporation pay its fair share of taxes...

This is a well needed research and I'm sure that with $1B in research, I'm sure that we will see even greater strides toward the cure and treatment of this disease.

I was surprised though to see that the United Kingdom houses GE's healthcare operation. Actually they are very well established in may countries. Perhaps someday in the near future they will relocate some of those businesses back to this country.

Quoted Text

With operations in the UK since the 1930s, GE has seen accelerated growth of its business here in recent years. The company has invested over £10 billion in UK business through acquisitions since 2002. Two of GE's global headquarters are also based in the UK, GE Healthcare in Amersham and GE Money in London. GE now has more than 45 locations in the UK, including 25 manufacturing facilities.

http://www.ge.com/uk/company/factsheet_uk.html

The $1B is research dollars.  Much of that will be spent in North Greenbush and Niskayuna.

because they are the machine for national healthcare just as they have been a government machine for military and the like.